http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Quasi-monolithic toroidal cross-capacitor
Lee, Rae Duk,Kim, Han Jun,Semenov, Y.P. IEEE 2005 IEEE transactions on instrumentation and measureme Vol.54 No.2
A quasi-monolithic toroidal cross-capacitor has been developed as an extremely stable and reliable capacitance standard of 0.5 pF. A geometrically symmetrical electrode structure is realized by using two identical plated substrates produced from fused silica with an exceedingly low thermal expansion coefficient. The capacitance instability expected after finishing the aging process does not exceed 5 × 10<SUP>-8</SUP> per year. Investigations have shown that the capacitor developed for evaluation of the frequency dependence of the calculable cross-capacitor developed by Korea Research Institute of Standards and Science (KRISS), Daejeon, Korea, can be used as a substitute to maintain the capacitance unit, as well as a loss angle standard and a transfer standard to carry out intercomparisons.
Hyun Suk Lee,Si Eun Park,Sang Bin Lee,Hee Joon Shin,Hee Joon Shin,Hong Rae Kim,Young Duk Choi,Kyung Ok Min 국제물리치료학회 2014 Journal of International Academy of Physical Ther Vol.5 No.2
This study was conducted to investigate the effect of FES and ankle mobilization on the ankle motion and the quality of gait of chronic hemiplegic patients with limited ankle joint motions. As research subjects, 24 chronic hemiplegic patients who could walk independently, regardless of assistive aids, were selected. Then, 8 subjects received mobilization randomly and 8 subjects received FES and 8 subjects received mobilization and FES, at the same time. The dorsiflexion PROM significantly increased in the group of mobilization therapy, mobilization and FES all together(p<.01). There were statistically significant differences among the three groups(p<.01). The 10m walking test significantly decreased in the group of mobilization therapy, mobilization and FES all together(p<.05). There were statistically significant differences among the three groups(p<.01). The gait velocity significantly increased in the group of mobilization therapy, FES therapy, mobilization and FES all together(p<.05). There were statistically significant differences among the three groups(p<.01). The stride length significantly increased in the group of mobilization therapy, mobilization and FES all together(p<.05). There were statistically significant differences among the three groups(p<.05). In conclusion, these findings demonstrate that rather than only using one treatment technique, applying mobilization and FES together brings a more satisfactory result to hemiplegic patients with limited ankle joint motions.
갈색세포종의 c - Myc , c - Fos 와 c - Jun 종양 단백질에 대한 면역조직화학적 연구
김태승,허갑범,이현철,임승길,이은직,이관우,김경래,송영득,남문석,남수연,조재화,이용희 대한내분비학회 1995 Endocrinology and metabolism Vol.10 No.1
A large number of studies for genes involved in oncogenesis have been done during last decade. Over 20 oncogenes have been isolated characterized, and the oncogene expressions in human tumors have been examined. The proto-oncogenes of c-Myc, c-Fos and c-Jun, which modulate the transcription factors, have overexpressed in a variety of human cancers. Immunohistochemical method was used in this study to examine c-Myc, c-Fos and c-Jun oncoprotein expression in 31 patients with human pheochromocytoma 28(90.0%) were benign and 3(10.0%) malignant. C-Myc oncoprotein immunoreactivity was found in 24 cases(77.4%), c-Fos in 29(93.5%), and c-Jun in 25(80.6%). Twenty-one(67.7%) showed positive immunoreactivity for all these oncoproteins, six(19.4%) for 2 oncoproteins, 3 for one oncoprotein. Only 1 case showed negative immunoreactivity for all 3 oncoproteins. The oncoprotein immunoreactivity did not correlate with the amount of 24 hour urinary catecholamine excretion. Although the number of malignant pheochromocytomsa was not so many, most of them showed that the immunoreactivity for oncoprotein was more than 30 percent of tumor cells. The expression of c-Myc, c-Fos and c-Jun oncoprotein were frequently found in human pheochromocytoma. These results suggest that the oncoprotein expression may play an important role in tumorogenesis and proliferation of human pheochromocytoma(J Kor Soc Endocrinol 10: 26-34, 1995).
임승길,김경래,정윤석,이경미,김동익,김현만,이현철,이은직,안광진,김덕희,윤도훔,박용구,김영수,정상섭,이규창,정우희,김태승,허갑범 대한내분비학회 1992 Endocrinology and metabolism Vol.7 No.4
TSH secreting pituitary adenoma is a rare disorder and represents about 1% of all pituitary adenomas. About 80 cases have so far been reported. We experienced four cases of TSH secreting pituitary adenoma. Three of them were macroadenomas and 1 was microadenoma. Serum TSH levels varied between 4.1~185.6 uIU/ml. The serum -subunit levels of two patients tested were slightly elevated (0.87, 0.96 mIU/ml). Serum TSH and -subunit response to TSH, dexamethasone, T3, bromocriptine, and octreotide were variable when studied. Three patients underwent transsphenoidal microsurgery. One of them received radiotherapy. They were cured. Treatment with octreotide in 1 patient who did not received surgery resulted in normalization of serum TSH and thyroid hormone levels and reduction in tumor size. (J Kor Soc Endocrinol 7:331~342, 1992)
Homeostasis Model Assessment법을 이용한 인슐린저항성 평가의 한계
이종호,허갑범,이현철,김경래,송영득,남재현,안철우,차봉수,박석원,윤용석,박효경,김오연,남수현,임승길 대한당뇨병학회 2000 Diabetes and Metabolism Journal Vol.24 No.5
Background: Homeostasis model assessment of insulin resistance (HOMA_(IR)) had been proposed as a simple and inexpensive alternative to other complex procedures measuring insulin resistance. We evaluated the validity of HOMA_(IR), comparing to total glucose disposal rate measured by euglycemic clamp test in 63 subjects with normal glucose tolerance, 21 with impaired glucose tolerance and 47 with type 2 DM. Methods: HOMA_(IR) and HOMA_(βcell function) (Homeostasis model assessment of βcell function) were calculated with formula described by Matthews (HOMA_(IR): fasting insulin (μU/mL) X fasting glucose (mmol/L) / 22.5, HOMA_(βcell function): 20 X fasting insulin (μpU/mL) / (fasting glucose (mmol/L) - 3.5)). 2-hour euglycemic (5 mmol/L) hyperinsulinemic (717 pmol/L) clamp test were carried out. Results: The strong inverse correlation (r=-0.658, $lt;0.001) was shown between log transformed HOMA_(IR) and total glucose disposal rates. The agreement of two methodes in the categorization according to insulin resistance was moderate (weighed κ=0.45). The magnitude of correlation coefficients were smaller in subjects with lower BMI (BMI $lt; 23.7 kg/㎡, r = -0.441 vs BMI ≥ 23.7 kg/㎡, r = -0.693, p = 0.0183), lower HOMA_(βcell function) (HOMA_(βcell function) $lt; 57.2, r = -0.514 vS HOMA_(βcell function) ≥ 57.2, r = -0.773, p = 0.0091) and higher fasting glucose levels (fasting glucose $lt; 102 mg/dL, r = -0.697 vs fasting glucose ≥ 102 mg/dL, r = -0.59, p = 0.0735). The results of correlation analysis was not significant in diabetics with lower BMI. Conclusion: Limitation of validity of HOMAIR should be carefully considered in subjects with lower BMI and lower fasting insulin to glucose levels, such as lean type 2 diabetes with insulin secretory defects.
비만인에서 베타3-아드레날린성 수용체 유전자변이에 따른 체지방 분포양상과 체중감량의 효과
이종호,허갑범,이현철,임승길,김경래,송영득,박석원,권석주,조은영 대한내분비학회 1998 Endocrinology and metabolism Vol.13 No.4
Background: Recently, missense mutation of the B3-adrenergic receptor gene has been shown to be associated with early onset of type 2 diabetes, abdominal obesity and an increased capacity to gain weight. This study was performed to investigate the effects of Trp64Arg mutation in the B3-adrenergic receptor gene on body fat distribution and weight loss in obese subjects. Methods: Determination of the B3-adrenergic receptor gene mutation with restriction enzyme digestion method, anthropometry, various biochemical studies, including oral glucose tolerance test were performed in 99 obese and 35 control subjects. Body fat distributions were also evaluated by computerized tomography before and after weight-reduction program. Results: I) There were no differences in the frequencies of Trp64Arg mutation in the B3-adrenergic receptor gene between obese and control subjects (15.2 vs 12.9 %). 2) The obese subjects with Trp64Arg mutation had higher waist to hip circumference ratio(WHR) (0.93 +- 0.05 vs 0.87 +- 0.04, p$lt;0.001), visceral fat area (115.0 +- 25.9 vs 86.4 +- 41.4 cm, p=0.01), but decreased plasma free fatty acid (618.0 +- 163.1 vs 817.5 +- 248.2 pEq/L, p=0.001), and triglyceride level (118.7 +- 36.2 vs 158.4 +- 105.8 mg/dL, p=0.015) than those without mutation. 3) The obese subjects with Trp64Arg mutation had smaller decreases in weight (-3.4 vs -5.1 kg, p$lt;0.001), body fat content (-2.1 vs -3.8 %, p$lt;0.001), WHR (-0.01 vs -0.03, p=0.025), and abdominal fat masses (total, subcutaneous, and visceral fat) after weight-reduction program than those without mutation. Conclusion: Trp64Arg mutation in the B3-adrenergic receptor gene might be one of genetic loci contributing to central obesity and a predictor of difficulty in losing weight in obese subjects. (J Kor Soc Endocrinol 13:590-600, 1998).